880 results on '"Rosenblat, Joshua D."'
Search Results
2. Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine
3. Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis
4. Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, placebo-controlled and delayed-start, neuroimaging trial in depression
5. Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine
6. Impact of Elevated Body Mass Index (BMI) on Hedonic Tone in Persons with Post-COVID-19 Condition: A Secondary Analysis
7. Dextromethorphan-Bupropion for the Treatment of Depression: A Systematic Review of Efficacy and Safety in Clinical Trials
8. Comparing suicide completion rates in bipolar I versus bipolar II disorder: A systematic review and meta-analysis
9. Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition: A secondary analysis
10. The association between ketamine and esketamine with alcohol and substance misuse: Reports to the Food and Drug Administration adverse event reporting system (FAERS)
11. Protocols and practices in psilocybin assisted psychotherapy for depression: A systematic review
12. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
13. Effects of anhedonia on health-related quality of life and functional outcomes in major depressive disorder: A systematic review and meta-analysis
14. Effects of ketamine on metabolic parameters in depressive disorders: A systematic review
15. Association between cognitive functioning, suicidal ideation and suicide attempts in major depressive disorder, bipolar disorder, schizophrenia and related disorders: A systematic review and meta-analysis
16. A replication study using the World Health Organization pharmacovigilance database (VigiBase®) to evaluate whether an association between ketamine and esketamine and alcohol and substance misuse exists
17. Preclinical and clinical efficacy of kappa opioid receptor antagonists for depression: A systematic review
18. Spectral signatures of psilocybin, lysergic acid diethylamide (LSD) and ketamine in healthy volunteers and persons with major depressive disorder and treatment-resistant depression: A systematic review
19. A comparison between psilocybin and esketamine in treatment-resistant depression using number needed to treat (NNT): A systematic review
20. Depression, anxiety and post-traumatic stress during the 2022 Russo-Ukrainian war, a comparison between populations in Poland, Ukraine, and Taiwan
21. Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin
22. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data
23. Association of SARS-CoV-2 infection with neurological impairments in pediatric population: A systematic review
24. Peripheral inflammatory biomarkers define biotypes of bipolar depression
25. Association between rumination, suicidal ideation and suicide attempts in persons with depressive and other mood disorders and healthy controls: A systematic review and meta-analysis
26. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis
27. Clinical efficacy and safety of Zuranolone (SAGE-217) in individuals with major depressive disorder
28. Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING)
29. COVID-19 vaccination for the prevention and treatment of long COVID: A systematic review and meta-analysis
30. Evaluating the Use of Glucagon-Like Peptide 1 for the Treatment of Cognitive Dysfunction in Individuals with Mood Disorders
31. A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review
32. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder
33. Association of a low protein diet with depressive symptoms and poor health-related quality of life in CKD
34. Evaluating the neural substrates of effort-expenditure for reward in adults with major depressive disorder and obesity
35. The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
36. Evaluating Anhedonia as a risk factor in suicidality: A meta-analysis
37. Lumateperone for the Treatment of Adults With Schizophrenia: a Systematic Review
38. The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits
39. Association between fatigue and depressive symptoms in persons with post-COVID-19 condition: a post hoc analysis
40. Association between dual orexin receptor antagonists (DORAs) and suicidality: reports to the united states food and drug administration adverse event reporting system (FAERS)
41. Risk of VMAT2 inhibitors on suicidality and parkinsonism: report utilizing the United States Food and Drug Administration adverse event reporting system
42. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 Update on Clinical Guidelines for Management of Major Depressive Disorder in Adults: Réseau canadien pour les traitements de l'humeur et de l'anxiété (CANMAT) 2023 : Mise à jour des lignes directrices cliniques pour la prise en charge du trouble dépressif majeur chez les adultes
43. Impact of Elevated Body Mass Index (BMI) on Cognitive Functioning and Inflammation in Persons with Post-COVID-19 Condition: A Secondary Analysis
44. Adjunctive cariprazine for major depressive disorder: a systematic review and meta-analysis
45. Number needed to treat (NNT) for ketamine and esketamine in adults with treatment-resistant depression: A systematic review and meta-analysis
46. Ketamine use in pediatric depression: A systematic review
47. Brain-Derived Neurotrophic Factor (BDNF) as a biomarker of treatment response in patients with Treatment Resistant Depression (TRD): A systematic review & meta-analysis
48. Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis
49. The abuse liability of ketamine: A scoping review of preclinical and clinical studies
50. Sex differences in ketamine's therapeutic effects for mood disorders: A systematic review
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.